Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(26 sites)

United States

Oruka Therapeutics Investigative Site, Phoenix, Arizona

Oruka Therapeutics Investigative Site, North Little Rock, Arkansas

Oruka Therapeutics Investigative Site, Los Angeles, California

Oruka Therapeutics Investigative Site, San Diego, California